Literature DB >> 21091189

Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth.

Xiaozhong Wang1, Jianming Zeng, Mei Shi, Shiqiao Zhao, Weijun Bai, Weixi Cao, Zhiguang Tu, Zonggan Huang, Wenli Feng.   

Abstract

The protein signal transducer and activator of transcription 5 (STAT5) of the JAK/STAT pathway is constitutively activated because of its phosphorylation by tyrosine kinase activity of fusion protein BCR-ABL in chronic myelogenous leukemia (CML) cells. This study investigated the potential therapeutic effect of STAT5 decoy oligodeoxynucleotides (ODN) using leukemia K562 cells as a model. Our results showed that transfection of 21-mer-long STAT5 decoy ODN into K562 cells effectively inhibited cell proliferation and induced cell apoptosis. Further, STAT5 decoy ODN downregulated STAT5 targets bcl-xL, cyclinD1, and c-myc at both mRNA and protein levels in a sequence-specific manner. Collectively, these data demonstrate the therapeutic effect of blocking the STAT5 signal pathway by cis-element decoy for cancer characterized by constitutive STAT5 activation. Thus, our study provides support for STAT5 as a potential target downstream of BCR-ABL for CML treatment and helps establish the concept of targeting STAT5 by decoy ODN as a novel therapy approach for imatinib-resistant CML.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21091189      PMCID: PMC3031259          DOI: 10.1089/dna.2010.1112

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  26 in total

Review 1.  The biology of chronic myeloid leukemia.

Authors:  S Faderl; M Talpaz; Z Estrov; S O'Brien; R Kurzrock; H M Kantarjian
Journal:  N Engl J Med       Date:  1999-07-15       Impact factor: 91.245

2.  DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites.

Authors:  E Soldaini; S John; S Moro; J Bollenbacher; U Schindler; W J Leonard
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation.

Authors:  R L Ilaria; R G Hawley; R A Van Etten
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

4.  Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells.

Authors:  Xiaolei Zhang; Peishu Liu; Bo Zhang; Ancong Wang; Meixiang Yang
Journal:  Cancer Genet Cytogenet       Date:  2010-02

5.  Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.

Authors:  Sangkil Nam; Ann Williams; Adina Vultur; Alan List; Kapil Bhalla; David Smith; Francis Y Lee; Richard Jove
Journal:  Mol Cancer Ther       Date:  2007-04       Impact factor: 6.261

6.  Overexpression of SERTAD3, a putative oncogene located within the 19q13 amplicon, induces E2F activity and promotes tumor growth.

Authors:  H Darwish; J M Cho; M Loignon; M A Alaoui-Jamali
Journal:  Oncogene       Date:  2007-01-29       Impact factor: 9.867

7.  NF-kappaB decoy oligonucleotides suppress RANTES expression and monocyte chemotactic activity via NF-kappaB inactivation in stromal cells of ectopic endometrium.

Authors:  Wang Xiu-li; Han Su-ping; Dai Hui-hua; You Zhi-xue; Fu Shi-long; Lu Pin-hong
Journal:  J Clin Immunol       Date:  2009-01-27       Impact factor: 8.317

8.  Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.

Authors:  Matthew P Strout; David G Schatz
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

9.  Nuclear heat shock protein 72 as a negative regulator of oxidative stress (hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and release.

Authors:  Daolin Tang; Rui Kang; Weimin Xiao; Lei Jiang; Meidong Liu; Yongzhong Shi; Kangkai Wang; Haichao Wang; Xianzhong Xiao
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

10.  STAT5 signaling is required for the efficient induction and maintenance of CML in mice.

Authors:  Dan Ye; Nicholas Wolff; Li Li; Shumin Zhang; Robert L Ilaria
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

View more
  13 in total

Review 1.  Therapeutic modulators of STAT signalling for human diseases.

Authors:  Gabriella Miklossy; Tyvette S Hilliard; James Turkson
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

Review 2.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

Review 3.  Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.

Authors:  Francis Leblanc; Dan Zhang; Xin Liu; Thomas P Loughran
Journal:  Future Oncol       Date:  2012-07       Impact factor: 3.404

Review 4.  Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Authors:  Sarah D Cramer; Peter D Aplan; Scott K Durum
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

Review 5.  Nucleic acid-based approaches to STAT inhibition.

Authors:  Malabika Sen; Jennifer R Grandis
Journal:  JAKSTAT       Date:  2012-10-01

Review 6.  STAT signaling in the pathogenesis and treatment of myeloid malignancies.

Authors:  Michal Bar-Natan; Erik A Nelson; Michael Xiang; David A Frank
Journal:  JAKSTAT       Date:  2012-04-01

7.  Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.

Authors:  Axel Weber; Corina Borghouts; Christian Brendel; Richard Moriggl; Natalia Delis; Boris Brill; Vida Vafaizadeh; Bernd Groner
Journal:  Cancers (Basel)       Date:  2015-03-19       Impact factor: 6.639

Review 8.  The role of the JAK-STAT pathway and related signal cascades in telomerase activation during the development of hematologic malignancies.

Authors:  Osamu Yamada; Kiyotaka Kawauchi
Journal:  JAKSTAT       Date:  2013-06-12

9.  Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells.

Authors:  Ahmad Hamad; Zeyad Sahli; Maya El Sabban; Maha Mouteirik; Rihab Nasr
Journal:  Stem Cells Int       Date:  2013-07-09       Impact factor: 5.443

Review 10.  STAT inhibitors for cancer therapy.

Authors:  Muhammad Furqan; Akintunde Akinleye; Nikhil Mukhi; Varun Mittal; Yamei Chen; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-12-05       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.